Clinical trial · Interventional
Phenoxodiol in Treating Patients With Refractory Solid Tumors
Phase IB Study of Phenoxodiol Given by Constant Intravenous Infusion in Patients With Solid Neoplasms (With the Exception of Breast Cancer) Whose Tumors Are Refractory to Standard Therapy
NCT00022295CI-TRIAL-00009831completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| idronoxil | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumor * Refractory to standard therapy OR * No standard therapy exists * No breast cancer * No active CNS metastases * Known CNS metastases must be previously treated with radiotherapy or surgery and stable for at least 4 weeks prior to study PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 60-100% Life expectancy: * At least 3 months Hematopoietic: * Platelet count greater than 100,000/mm\^3 * WBC greater than 3,000/mm\^3 * Neutrophil count greater than 1,500/mm\^3 * Hemoglobin greater than 10 g/dL (9 g/dL for women) Hepatic: * Bilirubin less than 1.2 mg/dL * Transaminases no greater than 3 times upper limit of normal Renal: * Creatinine no greater than 1.4 mg/dL Other: * No active infection * No contraindication to the insertion of a vascular access device * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent systemic anticancer immunotherapy Chemotherapy: * No concurrent systemic anticancer chemotherapy Endocrine therapy: * No concurrent systemic anticancer hormonal therapy except luteinizing hormone-releasing hormone agonists or antagonists Radiotherapy: * See Disease Characteristics * Concurrent localized radiotherapy for control of local disease complications allowed Surgery: * See Disease Characteristics Other: * Recovered from prior antineoplastic therapy * At least 4 weeks since prior investigational agents * No other concurrent investigational drugs
References
Publications (0)
Data not yet available
No reference posted for this study.